Information:
Fel:
ID
31597
Beskrivning
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002); ODM derived from: https://clinicaltrials.gov/show/NCT00777959
Länk
https://clinicaltrials.gov/show/NCT00777959
Nyckelord
Versioner (1)
- 2018-09-10 2018-09-10 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
10 september 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Prostate Cancer NCT00777959
Eligibility Prostate Cancer NCT00777959
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00777959
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Adenocarcinoma of prostate
Item
confirmed adenocarcinomas of the prostate.
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis
Item
evidence of metastatic disease
boolean
C0027627 (UMLS CUI [1])
Disease Progression | Raised prostate specific antigen | Disorder of lymph node Progressive | Bone scan Worsening
Item
evidence of disease progression including one of the following: increasing levels of psa, progressive lymph node disease, or worsening bone scan
boolean
C0242656 (UMLS CUI [1])
C0178415 (UMLS CUI [2])
C0272394 (UMLS CUI [3,1])
C0205329 (UMLS CUI [3,2])
C0203668 (UMLS CUI [4,1])
C0332271 (UMLS CUI [4,2])
C0178415 (UMLS CUI [2])
C0272394 (UMLS CUI [3,1])
C0205329 (UMLS CUI [3,2])
C0203668 (UMLS CUI [4,1])
C0332271 (UMLS CUI [4,2])
Prostate specific antigen measurement
Item
psa level is greater or equal to 7 ng/ml.
boolean
C0201544 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status less than or equal to 1
boolean
C1520224 (UMLS CUI [1])
Exclusion Criteria
Item
exclusion criteria :
boolean
C0680251 (UMLS CUI [1])
bicalutamide | Flutamide | nilutamide
Item
previously received bicalutamide, flutamide, or nilutamide within the past 12 months (except for a period of use less than 30 days long).
boolean
C0285590 (UMLS CUI [1])
C0016384 (UMLS CUI [2])
C0068771 (UMLS CUI [3])
C0016384 (UMLS CUI [2])
C0068771 (UMLS CUI [3])
Prior Chemotherapy Prostate carcinoma
Item
prior chemotherapy for prostate cancer
boolean
C1514457 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,2])
Sirolimus | Sirolimus Analogs | ridaforolimus | everolimus | temsirolimus
Item
prior rapamycin or rapamycin analogs, including ridaforolimus, everolimus, or temsirolimus.
boolean
C0072980 (UMLS CUI [1])
C0072980 (UMLS CUI [2,1])
C0243071 (UMLS CUI [2,2])
C2713007 (UMLS CUI [3])
C0541315 (UMLS CUI [4])
C1707080 (UMLS CUI [5])
C0072980 (UMLS CUI [2,1])
C0243071 (UMLS CUI [2,2])
C2713007 (UMLS CUI [3])
C0541315 (UMLS CUI [4])
C1707080 (UMLS CUI [5])
Opioids Pain | Narcotic Analgesics Pain | Pain Due to Prostate carcinoma
Item
patient is receiving an opioid or narcotic analgesic for pain due to prostate cancer
boolean
C0242402 (UMLS CUI [1,1])
C0030193 (UMLS CUI [1,2])
C0027409 (UMLS CUI [2,1])
C0030193 (UMLS CUI [2,2])
C0030193 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0600139 (UMLS CUI [3,3])
C0030193 (UMLS CUI [1,2])
C0027409 (UMLS CUI [2,1])
C0030193 (UMLS CUI [2,2])
C0030193 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0600139 (UMLS CUI [3,3])
Pain Relationship Prostate carcinoma | Initiation Chemotherapy Required
Item
patient has pain related to prostate cancer that warrants the initiation of chemotherapy
boolean
C0030193 (UMLS CUI [1,1])
C0439849 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C1704686 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
C0439849 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C1704686 (UMLS CUI [2,1])
C0392920 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])